Bimatoprost
Bimatoprost is a prostaglandin analog eye medication used to lower elevated eye pressure in open-angle glaucoma and ocular hypertension, and to treat inadequate eyelash growth.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 19 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
📖 Bimatoprost: Patient Information Guide
A plain-language walkthrough of Bimatoprost — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.
🎯What it's used for▾
Bimatoprost is available in several products approved for different uses — not every form treats every condition.
- Lumigan (eye drops): reduces elevated intraocular pressure in open-angle glaucoma or ocular hypertension
- Zolymbus (eye ointment): reduces elevated intraocular pressure in open-angle glaucoma or ocular hypertension
- Durysta (intracameral implant): reduces intraocular pressure in open-angle glaucoma or ocular hypertension — given as a one-time implant inside the eye by a clinician
- Latisse (eye drops applied topically): treats hypotrichosis of the eyelashes — sparse, thin, or short lashes — by increasing their length, thickness, and darkness
- Bimatoprost ophthalmic solution 0.03%: also approved to treat hypotrichosis of the eyelashes
⚙️How it works▾
Bimatoprost is a synthetic prostaglandin analog — meaning it's built to mimic natural substances in the body called prostamides. For glaucoma and high eye pressure, it works by opening up the eye's drainage channels (called the trabecular meshwork and uveoscleral routes), letting excess fluid called aqueous humor drain out more easily. Less fluid inside the eye means lower pressure, which protects the optic nerve from damage and helps preserve vision.
💊How it's taken▾
The right way to take bimatoprost depends on which product your doctor prescribes — do not mix up instructions between products.
- Lumigan eye drops: one drop in the affected eye(s) once each evening — never more than once daily
- Zolymbus eye ointment: one drop from a single-dose container in the affected eye(s) once each evening; open and use immediately, then discard the container
- Latisse / bimatoprost 0.03% for lashes: applied once nightly to the upper eyelid skin at the lash base using a sterile applicator; use a fresh applicator for each eye and discard after use
- Durysta implant: a one-time procedure performed by a healthcare provider; the implant should not be repeated in the same eye
If you miss a dose of an eye drop or ointment, just continue with your next scheduled dose — don't double up. Always follow your prescriber's specific directions.
🤒Side effects — in detail▾
The most common side effects affect the eyes and are often mild, but some changes can be permanent.
- Eye redness (the most common side effect, seen in up to 45% of users)
- Increased eyelash growth or darkening
- Eye itching
- Eye dryness, burning, or foreign body sensation
- Darkening of the skin around the eye or eyelids (usually reversible when stopped)
- Darkening or color change of the iris — this may be permanent
- Eye pain or visual disturbance
- Colds or upper respiratory infections (about 10% of users)
Seek medical attention if you notice sudden vision changes, signs of eye inflammation (pain, redness, light sensitivity), swelling around the eye, or signs of an allergic reaction such as severe redness or skin rash.
⚠️Warnings & precautions▾
- Permanent iris color change: Bimatoprost can cause the iris to become more brown over time. This can affect one or both eyes and may take months to years to appear. It is likely irreversible — meaning it stays even after you stop the medication. If you use it in only one eye, that eye may permanently end up a different color than the other.
- Eyelid and skin darkening: The skin around the eye and the eyelashes can darken with use. Unlike iris changes, this darkening of the eyelid skin is usually reversible when treatment stops.
- Unwanted hair growth: If the solution regularly contacts skin outside the upper eyelid (like the cheek), hair may grow in those areas. Careful application and blotting of any excess is important.
- Eye inflammation: Use with caution if you have active uveitis (inflammation inside the eye) — bimatoprost may worsen it.
- Macular edema: Swelling at the center of the retina has been reported, especially in people who've had certain eye surgeries or have risk factors. Tell your doctor your full eye history.
- Interaction with other prostaglandin eye drops: Using bimatoprost alongside another prostaglandin analog can reduce the eye pressure-lowering effect of both.
🔀What it interacts with▾
Bimatoprost has a few important interactions to be aware of, mostly involving other eye medications.
- Other prostaglandin analog eye drops (e.g., Lumigan, Travatan, Xalatan): Using bimatoprost alongside another drug in this class can reduce how well either one lowers eye pressure — your doctor needs to know about all eye drops you use.
- Other topical eye drops in general: If you use more than one eye drop, wait at least 5 minutes between each to avoid washing one out before it works.
- Soft contact lenses: Some bimatoprost eye drop products contain benzalkonium chloride, a preservative that can be absorbed by soft contact lenses and cause discoloration. Remove lenses before applying drops and wait 15 minutes before putting them back in.
This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.
📋Before taking it▾
- Allergy: Do not use bimatoprost if you are allergic to it or to any ingredient in the product.
- Eye inflammation: Tell your doctor if you have uveitis or other active eye inflammation — bimatoprost may make it worse.
- Recent eye surgery or lens issues: If you've had lens surgery (aphakia or pseudophakia with a torn capsule) or are at risk for macular edema, discuss this with your doctor first.
- Pregnancy: There are no adequate studies in pregnant people. Animal studies at high doses showed risks, but those doses were far higher than typical eye drop exposure. Use only if your prescriber decides the benefit justifies the risk.
- Breastfeeding: It's not known whether bimatoprost passes into human breast milk in significant amounts. Discuss with your doctor.
- Children: Bimatoprost ophthalmic solution 0.03% has been studied for eyelash growth in children ages 5–17 in certain conditions; discuss pediatric use with a prescriber.
- Older adults: No significant differences in safety or effectiveness have been seen between older and younger adults.
🚑If you take too much▾
There is no information on what happens if a person takes too much bimatoprost. If an overdose occurs, treatment is focused on managing whatever symptoms appear — there is no specific antidote. In animal studies, very high oral doses did not cause toxicity, and the amount in one bottle is well below concerning levels even for a child. If you're worried about accidental exposure, contact Poison Control or seek medical advice.
📡Pharmacodynamics — effects in the body▾
Bimatoprost lowers intraocular pressure by increasing how much fluid drains out of the eye through two routes: the trabecular meshwork and the uveoscleral pathway. For eye drop products, pressure reduction begins about 4 hours after the first dose, with the maximum effect reached within 8 to 12 hours. Using more than one dose per day does not increase the benefit — in fact, it may actually reduce the pressure-lowering effect, which is why once-daily dosing is recommended.
🔬Pharmacokinetics — how your body processes it▾
When bimatoprost eye drops are applied to the eye, a small amount is absorbed into the bloodstream. Blood levels peak within about 10 minutes of dosing and fall below detectable levels within 1.5 hours in most people — meaning very little drug accumulates in the body over time. Once in the bloodstream, bimatoprost is broken down (metabolized) by the liver through oxidation and other processes. About 67% of the drug is eventually cleared through the urine and 25% through the feces. The elimination half-life (the time it takes for half the drug to leave the blood) is approximately 45 minutes.
📦How to store it▾
Store at 2°C to 25°C (36°F to 77°F).
📄 Written from Bimatoprost’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →
🩺 Pharmacist Counseling Corner
Quick, plain-English answers to the questions patients ask most about Bimatoprost — the kind of thing our pharmacy team would talk through with you at the counter.
What is bimatoprost actually used for — I've heard it's for both glaucoma and eyelashes? ▾
Will bimatoprost change the color of my eyes? ▾
Can bimatoprost cause hair to grow in places I don't want? ▾
Can I use bimatoprost with other eye drops I already take? ▾
I wear contact lenses — is it safe to put them in before using these eye drops? ▾
Is it safe to use bimatoprost if I'm pregnant or breastfeeding? ▾
Is Bimatoprost available over the counter? ▾
When was Bimatoprost first available? ▾
Who makes Bimatoprost? ▾
💬 Answers drafted from Bimatoprost’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →
🧰 Keep exploring
💊 How Bimatoprost comes
Bimatoprost is available in 4 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Eye drops
How this form is used
- Lumigan is used to reduce elevated intraocular pressure in open-angle glaucoma or ocular hypertension
- Latisse is used to treat hypotrichosis of the eyelashes — increasing their length, thickness, and darkness
- Bimatoprost ophthalmic solution 0.03% is used to treat hypotrichosis of the eyelashes by increasing their growth
- Lumigan: instill one drop into the affected eye(s) once daily in the evening; do not use more than once daily
- Latisse: apply once nightly to the upper eyelid margin at the base of the lashes using the supplied sterile applicator; do not apply to the lower lash line
- Bimatoprost ophthalmic solution 0.03% for lashes: apply one drop to the sterile applicator and use along the upper eyelid margin nightly; discard applicator after one use per eye
- If wearing soft contact lenses, remove them before applying eye drops and wait 15 minutes before reinserting
Insert or device
How this form is used
- Durysta is used to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension
- Durysta is administered as a single implant injected into the front chamber of the eye by a healthcare provider under sterile conditions
- Durysta should not be given a second time to an eye that has already received it
Topical solution
Eye ointment
How this form is used
- Zolymbus is used to reduce elevated intraocular pressure in open-angle glaucoma or ocular hypertension
- Zolymbus: use one drop from the single-dose container into the affected eye(s) once daily in the evening
- Zolymbus: do not use more than once daily — more frequent dosing may reduce the eye pressure-lowering effect
- Zolymbus: use the container immediately after opening and discard it along with any remaining contents right after use
- Zolymbus: if using other topical eye drops at the same time, wait at least 5 minutes between each medication
📊 Bimatoprost across the U.S. market
How Bimatoprost appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Also listed with the FDA, not a patient dose form: Powder (26) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
📈 How widely Bimatoprost is used
A general measure of how commonly Bimatoprost is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Bimatoprost is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Bimatoprost prescribed? Of the 1,596 medications we measure, Bimatoprost ranks #648 by Medicaid prescriptions — more than 59% of them.
Utilization by Bimatoprost product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
bimatoprost 0.1 MG/ML Ophthalmic Solution Most dispensed
Summed across the 3 of 12 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1009339
bimatoprost 0.3 MG/ML Ophthalmic Solution
Summed across the 10 of 29 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 308739
bimatoprost 0.01 MG Drug Implant
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2286602
bimatoprost 0.3 MG/ML Topical Solution
Summed across the 2 of 9 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1041495
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Bimatoprost, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 16 of 52 listed Bimatoprost NDCs with Medicaid activity.
🔍 Compare Bimatoprost products
A representative set of FDA-listed product records for Bimatoprost — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Eye drops | ||||
| 0.3 mg/mL | Ophthalmic | Akorn | ANDA | View NDC → |
| 0.3 mg/mL | Ophthalmic | Alembic Pharmaceuticals Inc. × 6 listings | ANDA | View NDC → |
| 0.3 mg/mL | Ophthalmic | Alembic Pharmaceuticals Limited × 2 listings | ANDA | View NDC → |
| 0.1 mg/mL | Ophthalmic | Allergan, Inc. × 3 listings | NDA | View NDC → |
| 0.3 mg/mL | Ophthalmic | Allergan, Inc. × 3 listings | NDA | View NDC → |
| 0.1 mg/mL | Ophthalmic | Amneal Pharmaceuticals NY LLC | ANDA | View NDC → |
| 0.3 mg/mL | Ophthalmic | Apotex Corp. × 3 listings | ANDA | View NDC → |
| 0.3 mg/mL | Ophthalmic | Aurobindo Pharma Limited × 2 listings | ANDA | View NDC → |
| 0.1 mg/mL | Ophthalmic | First Nation Group, LLC | ANDA | View NDC → |
| 0.3 mg/mL | Ophthalmic | Fosun Pharma USA Inc. × 6 listings | ANDA | View NDC → |
| 0.3 mg/mL | Ophthalmic | Gland Pharma Limited × 3 listings | ANDA | View NDC → |
| 0.1 mg/mL | Ophthalmic | Lifestar Pharma LLC × 3 listings | ANDA | View NDC → |
| 0.3 mg/mL | Ophthalmic | Lupin Pharmaceuticals, Inc. | ANDA | View NDC → |
| 0.3 mg/mL | Ophthalmic | Micro Labs Limited × 2 listings | ANDA | View NDC → |
| 0.3 mg/mL | Ophthalmic | NuCare Pharmaceuticals,Inc. × 2 listings | ANDA | View NDC → |
| 0.3 mg/mL | Ophthalmic | Sandoz Inc × 3 listings | ANDA | View NDC → |
| 0.3 mg/mL | Ophthalmic | Somerset Therapeutics, LLC × 9 listings | ANDA | View NDC → |
| 💊Eye ointment | ||||
| 0.1 mg/g | Ophthalmic | Thea Pharma Inc. | NDA | View NDC → |
| 💊Insert or device | ||||
| 10 mcg | Intracameral | Allergan, Inc. × 3 listings | NDA | View NDC → |
| 10 mcg | — | Synergy Health AST, LLC | DRUG FOR FURTHER PROCESSING | View NDC → |
| 💊Topical solution | ||||
| 3 mcg/mL | Topical | Akorn × 2 listings | ANDA | View NDC → |
| 💊Bulk drug substance | ||||
| 1 g/g | — | AX Pharmaceutical Corp | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 1 kg/kg | — | C-squared Pharma Limited | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Cayman Pharma s.r.o. | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Chirogate International Inc | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Darmerica, Llc × 2 listings | BULK INGREDIENT | View NDC → |
| 1 g/g | — | EUROAPI Hungary Ltd. | BULK INGREDIENT | View NDC → |
| 0.2 g/0.2 g | — | Everlight Chemical Industrial Corporation Kuanyin II Plant | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | FDC Limited | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | Industriale Chimica s.r.l. × 2 listings | BULK INGREDIENT | View NDC → |
| 100 kg/100 kg | — | Kyowa Pharma Chemical Co., Ltd. | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | Laurus Labs Limited | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Letco Medical, Llc × 2 listings | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 1 kg/kg | — | Maprimed S.A. | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Medisca Inc. × 2 listings | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | MSN Laboratories Private Limited | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Newchem Spa | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | Piramal Healthcare (Canada) Limited | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Qingdao Biopeptek Co., Ltd. | BULK INGREDIENT | View NDC → |
| 1 g/g | — | SciAnda(Changshu) Pharmaceuticals, Ltd. | BULK INGREDIENT | View NDC → |
| 1 g/g | — | ScinoPharm Taiwan Ltd. | BULK INGREDIENT | View NDC → |
| 1 g/g | — | YS Life Science Co., Ltd. | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Zhejiang Ausun Pharmaceutical Co., Ltd. | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
Showing 84 of 84 products — FDA National Drug Code Directory. See every product, package size and price: browse all 84 Bimatoprost NDCs →
📈 What people report — real-world data (FDA FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Bimatoprost — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Bimatoprost in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
🏛️ The road to your pharmacy
How Bimatoprost went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
🚨 Recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
Source: openFDA drug enforcement (recall) reports.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 283810 4 dose forms · 5 strengths
-
Dose form (SCDF) Drug Implant RxCUI 2286601In current FDA listingsClinical drug / strength (SCD) 0.01 MGRxCUI 2286602 -
Dose form (SCDF) Ophthalmic Gel RxCUI 2725167In current FDA listingsClinical drug / strength (SCD) 0.0001 MG/MGRxCUI 2725168 -
Dose form (SCDF) Ophthalmic Solution RxCUI 378341In current FDA listings -
Dose form (SCDF) Topical Solution RxCUI 1041494In current FDA listingsClinical drug / strength (SCD) 0.3 MG/MLRxCUI 1041495
Look up RxCUI 283810 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
📦 Supply & shortage status
Whether Bimatoprost is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
🏷️ Sold under these brand names
🏭 Manufacturers & labelers
…and 16 more on the FDA NDC directory.
RxNorm drug class
Bimatoprost belongs to the Prostaglandin Analog class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
🔬 Where this comes from
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How we combine label and product data
HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 19 FDA-filed SPL label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.
For canonical ingredient pages, bounded product-attributed indication and administration excerpts may be added to the AI evidence, and the generator is instructed to preserve available product, brand, route, and form qualifiers instead of treating one label as universal. Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. Allergan, Inc. is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.
This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.